Abstract Number: 307 • 2017 ACR/ARHP Annual Meeting
Biochemical Intervertebral Disc Alterations in Patients with Low Back Pain and Radiculopathy
Background/Purpose: To assess the glycosaminoglycan (GAG) content of lumbar intervertebral discs (IVD) in patients with low back pain (LBP) and radiculopathy using glycosaminoglycan chemical exchange…Abstract Number: 308 • 2017 ACR/ARHP Annual Meeting
Frequency, Morbidity and Healthcare Utilization of Diffuse Idiopathic Skeletal Hyperostosis (DISH) Patients at a University Hospital
Background/Purpose: DISH is a non-inflammatory condition affecting the spine, and characterized by ossification of paravertebral ligaments. DISH is traditionally considered asymptomatic, detected incidentally on spine…Abstract Number: 309 • 2017 ACR/ARHP Annual Meeting
Compression Assisted Arthrocentesis and Intraarticular Injection
Background/Purpose: We hypothesized that compression assisted arthrocentesis of the knee would improve arthrocentesis fluid yields and intraarticular injection outcomes.Methods: We performed conventional arthrocentesis on 215…Abstract Number: 310 • 2017 ACR/ARHP Annual Meeting
Comparison of Flexed and Extended Knee Arthrocentesis and the Role of Constant Compression
Background/Purpose: The objective of this study was to determine whether extended versus flexed knee position is superior for arthrocentesis. Methods: 55 clinically effusive knees with…Abstract Number: 311 • 2017 ACR/ARHP Annual Meeting
Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Background/Purpose: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft tissue balance, adjustment of the loading axis)…Abstract Number: 312 • 2017 ACR/ARHP Annual Meeting
Rates of Total Joint Replacement Utilization in the U.S.: Future Projections to 2020-2040 Using the National Inpatient Sample
Background/Purpose: To project the future utilization of total hip and knee joint arthroplasty (THA, TKA).Methods: We used the 2000-2010 U.S. National Inpatient Sample combined with…Abstract Number: 313 • 2017 ACR/ARHP Annual Meeting
The Effect of Obesity on Walking; Comparison of the Spatiotemporal, Kinematic and Kinetic Parameters of Young Obese and Non-Obese Healthy Women
Background/Purpose: Obesity is a risk factor for development of knee osteoarthritis due to altered gait biomechanics. Gait analysis was performed mostly on older obese adults…Abstract Number: 314 • 2017 ACR/ARHP Annual Meeting
Effects of Exercise on Anxiety in Adults with Arthritis: A Systematic Review with Meta-Analysis
Background/Purpose: Previous randomized controlled trials have led to conflicting findings regarding the effects of exercise on anxiety in adults with arthritis and other rheumatic diseases…Abstract Number: 315 • 2017 ACR/ARHP Annual Meeting
Efficacy of a Wearable-Enabled Physical Activity Counselling Program for People with Knee Osteoarthritis
Background/Purpose: Current guidelines emphasize an active lifestyle in the management of knee osteoarthritis (OA), but up to 90% of OA patients are inactive. Several modifiable…Abstract Number: 316 • 2017 ACR/ARHP Annual Meeting
Pain, Fatigue and Function in Patients with Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder – Relationship with Perceived Benefits and Barriers to Exercise
Background/Purpose: The Ehlers-Danlos Syndromes (EDS) are a heritable group of connective tissue disorders with predominant features including joint hypermobility, skin hyperextensibility and tissue fragility. Hypermobility…Abstract Number: 317 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Blood Transfusions Following Total Joint Arthroplasty in Patients with Rheumatoid Arthritis
Risk Factors for Blood Transfusions Following Total Joint Arthroplasty in Patients with Rheumatoid ArthritisAbstractBackground/Purpose: Despite effective therapies, rheumatoid arthritis (RA) can result in joint destruction…Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…Abstract Number: 319 • 2017 ACR/ARHP Annual Meeting
The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab
Background/Purpose: Romosozumab (Romo), a sclerostin antibody, has a dual effect of increasing bone formation and decreasing bone resorption. In the FRAME study, one year of…Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…Abstract Number: 321 • 2017 ACR/ARHP Annual Meeting
A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates
Background/Purpose: Four clinical trials have separately shown greater BMD gains with transitioning to denosumab (DMAb) compared with continuing on bisphosphonates (BP) in subjects previously treated…